SEC Form 4 · accession 0001127602-16-052229
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Francis Cogan
Director
Period of report
May 11, 2016
Accepted (ET)
May 13, 2016 · 7:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | May 11, 2016 | A | 1,787 | A | — | — | Common Stock | 1,787 | 1,787 | D |
| Non-qualified Stock Option (Right to Buy)F3 | $83.90 | May 11, 2016 | A | 7,321 | A | — | May 11, 2026 | Common Stock | 7,321 | 7,321 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F2100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting.
- F3Options vest quarterly over the first year of service upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting.